<unk>  is a humanized anti-interleukin-17 monoclonal antibody that is FDA approved for the treatment of of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.   Common adverse reactions include injection site reactions, upper respiratory tract infections, nausea, and tinea infections (≥1%).
Ixekizumab
Caplacizumab
Risankizumab
Tocilizumab
Emicizumab
Natalizumab
Atezolizumab
Bococizumab